Study looks at genetic background of healthy people who develop severe Covid-19 illness

Last Updated on

June 13, 2020 – To help disentangle the secrets of Covid-19 disease, researchers are sequencing the DNA of young grown-ups and children who suffer from extreme Covid-19 disease ailments in spite of having no hidden clinical issues. The scientists are searching for hereditary genetic risk factors that could put certain people at high danger of getting seriously sick from the novel coronavirus, i.e., SARS-CoV-2.. 

The McDonnell Genome Institute at Washington University School of Medicine in St. Louis is one of in excess of 30 genome sequencing centers overall taking an interest in these examinations. In the US, besides at  Washington University, the collaborative worldwide initiative called the COVID Human Genetic Effort (CHGE), is co-driven by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), and Rockefeller University.

The scientists additionally plan to contemplate individuals who never become tainted with SARS-CoV-2, the infection that causes Covid-19, in spite of rehashed exposures. Such people may have hereditary varieties that secure against disease. For instance, certain uncommon hereditary variations are known to impede a few kinds of viral contaminations, including HIV and norovirus. Information picked up from comprehension Covid-19’s limits such as unordinary weakness could prompt new restorative procedures for the disease. 

The main focal point of the researchers examination will be patients with extreme clinical reactions to SARS-CoV-2 infections, sufficiently serious to require concentrated clinical intervention and who are younger than 50 years. Such patients generally don’t have uncontrolled diabetes, coronary illness, incessant lung infection or other preexisting conditions that are known to expand the danger of serious complexities from Covid-19. Effectively, one learns about a long distance runner or a for the most part fit and well trained individual who became seriously ill from SARS-CoV-2 infection, or about a series of young and healthy kids who were becoming extremely ill with Covid-19, all without any hidden or overt predispositions for disease. These are the sorts of patients for research on genetic backgrounds as reasons for severe Covid-19 disease in young patients. Likely less than 10 % of all patients affected by Covid-19 will meet such clinical preselection criteria.

Particular risk for young people for Covid-19 disease may relate to existing yet hidden genetic predispositions for essential immunodeficiencies. To find such genetic risk loci, ideally, genome wide association studies (GWAS) encompassing populations of carefully selected patients exhibiting the searched for clinical endpoint(s), i.e., any forms of immunodeficiencies in the present setting,  would be the approach of choice. In fact, GWAS have recently shown their power to reveal genetic predispotions of patients for SARS-CoV-2 based Covid-19 development. Thus, in one of the first GWAS-studies, variants in both the ABO blood group locus and a cluster of genes on human chromosome 3 have been found to be more common among Covid-19 patients with respiratory failure than in the general population. Similarly, susceptibility loci in pathways of immune system function may be localised. Furthermore, more prospective evidence for patients susceptibilities will emerge from within the COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic.

Eventually, these concerted genetic approaches will lead to a sound body of understanding around SARS-CoV-2 and Covid-19, and how individuals may cope with this distinctive health challenge.

See here a sequence on susceptibility particularly looking at Covid-19:

Print Friendly, PDF & Email


Tags: , , , , , , , ,
About the Author
Joseph Gut - thasso Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.

Your opinion


No comments yet

thasso: conditions

thasso: newest tweets

thasso: recent comments

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Newly discovered mutation could point to heart disease therapeutic target August 7, 2020
    New work led by Carnegie's Meredith Wilson and Steve Farber identifies a potential therapeutic target for clogged arteries and other health risks that stem from an excess of harmful fats in the bloodstream. Their findings are published by PLOS Genetics.
  • Genetic cause of congenital malformation discovered August 7, 2020
    Spontaneous mutations of a single gene are likely to cause serious developmental disorders of the excretory organs and genitalia. This is shown in an international study led by the University of Bonn and published in the journal Frontiers in Cell and Developmental Biology. The researchers also owe their findings to an unusual model organism: the […]
  • Novel approach reduces SCA1 symptoms in animal model August 7, 2020
    Research has shown that a mutation in the ATAXIN-1 gene leads to accumulation of Ataxin-1 (ATXN1) protein in brain cells and is the root cause of a rare genetic neurodegenerative disease known as spinocerebellar ataxia type 1 (SCA1). How healthy cells maintain a precise level of ATXN1 has remained a mystery, but now a study […]
  • Alport Syndrome: Research highlights link between genotype and treatment effectiveness August 7, 2020
    A large-scale analysis of the clinical characteristics of Alport syndrome in Japanese patients has revealed that the effectiveness of existing treatment with ACE inhibitors and/or angiotensin receptor blockers (RAS inhibitors) varies depending on the type of mutation in the syndrome's causal gene (COL4A5). RAS inhibitors are widely administered to patients with chronic kidney diseases as […]
  • Tasmanian devil research offers new insights for tackling cancer in humans August 6, 2020
    A rare, transmissible tumor has brought the iconic Tasmanian devil to the brink of extinction, but new research by scientists at Washington State University and the Fred Hutchinson Cancer Research Center in Seattle indicates hope for the animals' survival and possibly new treatment for human cancers.
  • checkmate 743 shows that dual immunotherapy, nivolumab + ipilimumab August 8, 2020
    The combination of first-line nivolumab and ipilimumab demonstrated an improvement of overall survival for patients with unresectable malignant pleural mesothelioma compared to platinum-based chemotherapy, according to research presented today at the International Association for the Study of Lung Cancer Virtual Presidential Symposium.
  • Phase 3 eXalt3 study shows significantly longer progression-free survival August 8, 2020
    Patients with non-small cell lung cancer (NSCLC) carrying anaplastic lymphoma kinase (ALK) gene alterations who received ensartinib experienced substantially longer progression-free survival than a matched group of patients who received crizotinib.
  • Addition of sintilimab to pemetrexed and platinum improved progression-free survival August 8, 2020
    The interim analysis of ORIENT-11, a phase III double-blind randomized trial has shown a nearly two-fold increase in progression-free survival with addition of sintilimab to chemotherapy in patients with advanced or metastatic non-squamous non-small cell lung cancer without EGFR or ALK genomic aberrations, according to research data presented today at the International Association for the […]
  • Heart attack case rates, treatment approaches, outcomes during COVID-19 pandemic August 7, 2020
    The increases and decreases in patient volume and associated changes in treatment experienced by individuals presenting with acute heart attack (myocardial infarction) before and immediately after the onset of the COVID-19 pandemic are examined in this observational study.
  • COVID recovery choices shape future climate August 7, 2020
    A new international study, led by the University of Leeds, warns that even with some lockdown measures staying in place to the end of 2021, without more structural interventions global temperatures will only be roughly 0.01°C lower than expected by 2030. However, the study estimates that including climate policy measures as part of an economic […]